Mr. Jatin
Mahajan
Managing Director, J Mitra and Co. |
J Mitra Launches Covid-19
Total
Antibody Detection Elisa Test Kits |
• Redefines Elisa diagnosis in
Serum/Plasma samples to fight COVID-19
• Advanced Elisa technology based on Double-Sandwich Principle
• Production capacity of 5 Lakh Tests per day (1 Crore test
p.m.)
• ‘Made-in-India’ for Total Antibodies (IgM, IgG, IgA)
detection in COVID-19
• J Mitra has the highest number of patents in the Indian
market
J Mitra & Co. Pvt Ltd, India’s leading global
MNC in the In-Vitro Diagnostics (IVD) industry has launched
its state-of-the-art Covid-19 Test Kit in the Indian market.
Based on the Double Sandwich Elisa technology, the test kit is
known as COVID-19 [IgM, IgG, IgA]
MICROLISA. It is a serology-based total antibody (IgM,
IgG, IgA) detection assay. This factor makes the J Mitra
Corona Test kit superior and more accurate than other similar
tests available in the market. It is a detection assay for the
indirect diagnosis of past exposure to COVID-19. All the
Covid-19 antibodies are detected without a differentiation in
antibodies, and this is the reason contributing to the
superior performance of this test. Elisa tests are highly
sensitive and specific, and detect the COVID-19 antibodies in
patient blood samples. 96-tests can be performed in one single
go (using an instrument) and the test results are available
within 90 minutes.
The COVID-19 [IgM, IgG, IgA] MICROLISA Elisa
test kit has cleared all government parameters and received
all necessary approvals, including Indian Council of Medical
Research (ICMR) and Drug Controller General of India (DCGI).
Speaking on the latest offering from the J
Mitra stable, Lalit Mahajan, chairman said, “we have deployed
extensive indigenous R&D for the development of this unique
product. There has been substantial contribution in its
development by International Centre for Genetic Engineering &
Biotechnology (ICGEB) headed by Dr Navin Khanna. This is the
first time that a total antibody detection assay kit for
covid-19 has been developed in the Indian market. Using a
combination of IgM, IgG and IgA antibody test increases the
sensitivity, efficiency and efficacy of the test parameters,
providing a more accurate diagnosis as compared to other test
kits in the market.”
Talking about the accuracy of the J Mitra
covid-19 test kit, Lalit Mahajan further added, “The IgG
antibody takes approximately 14 days to form after an
infection, while IgM antibodies are the first antibody that
the body forms after approximately 7 days when it fights a new
infection. The presence of IgA antibodies in patient sample
also gets detected simultaneously, in this test kit. IgA is
considered a major effector in the defence mechanism against
viruses and induces efficient IgA antibodies response. Its
simultaneous detection along with IgM/IgG antibodies improves
sensitivity of the test kit. because of this, the J Mitra
covid-19 test
is a more potent diagnostic kit, providing an opportunity to
fight the disease during the pre-symptomatic phase and thus
mitigating further risk.”
Speaking on the production aspects, Jatin
Mahajan, managing director said, “We are ready to meet the
demand arising from all parts of the country. We have an
immediate production capacity of 5 lakh test kits daily (or 1
crore test kits per month), but we have a dynamic production
plant that can be augmented to double the production capacity
in 3 days.”
“The pricing of the kit is being worked out.
We are a socially conscious company with a 50-year legacy of
service to the nation - we will price it very competitive to
ensure that it is available for the masses through all
relevant government channels.”
“This is a completely indigenous kit – an
‘atmanirbhar’ initiative with R&D done inhouse, and sourcing
done from Indian manufacturers and suppliers. In keeping with
the Government’s make in India initiative, we have created the
most robust supply chain ecosystem for material sourcing as
well as for supplying to various government agencies as per
the demands”, he further added.
About J Mitra &
Company
Incorporated in 1969, this research-based
Indian biotechnology MNC has completed 51 years towards its
mission to serve mankind and is one of the leading IVD
companies globally. The company manufactures a range of tests
for infectious diseases like HIV, HBV, HCV, Dengue, Malaria,
Typhoid, Leptospira in rapid and ELISA test formats. The other
products include a range of Anti-Sera products and
confirmatory tests like Western Blot for HIV. Famous for its
innovation and R&D, the company has over 55 patents – highest
for any Indian company.
Apart from a pan-India footprint, J Mitra &
Company is also the biggest exporter of diagnostics kits from
India, and export to more than 45 countries across the entire
globe.
For further information please contact:
Prasun Peter @ 9811279008,
prasun.peter@gmail.com.
|